What cancer does Lorlatinib treat?

Lorlatinib is a targeted therapy drug mainly used to treat non-small cell lung cancer (NSCLC) with mutations in ALK (tyrosine kinase) and ROS1 (kinase). ALK and ROS1 mutations are common molecular features in some lung cancer patients, leading to abnormal activation of signaling pathways and promoting abnormal proliferation and survival of cancer cells.

For ALKpositiveNSCLC patients, abnormal activation of the ALK fusion gene plays an important role in the pathogenesis of lung cancer. By inhibiting the activity of ALK kinase, lorlatinib can block this abnormal signaling pathway and slow down or inhibit the growth of cancer cells. In addition, for ROS1positive NSCLC patients, lorlatinib also showed effective inhibition of ROS1kinase, thereby inhibiting the development of cancer.

Larlatinib is a new generation of ALK and ROS1 inhibitors. Compared with some early targeted drugs, it has higher selectivity and stronger anti-tumor activity. This makes lorlatinib of particular therapeutic value in patients who are resistant or intolerant to other treatment options.

Lorlatinib has been launched in China and is included in medical insurance. Patients can purchase it domestically, but the price is relatively high, about 10,000 to 20,000 yuan. For details, please consult the local hospital pharmacy. There are original lorlatinib drugs and cheaper generic drugs abroad. The cheaper ones are the original drug from Turkey, which costs more than 1,000 yuan, and the original drug from Hong Kong, China, which costs about 30,000 yuan. Generic drugs are mainly generic drugs from Laos and Bangladesh. The price is about several thousand yuan, and the ingredients of the original drugs and generic drugs are basically the same.